For PTC, Future Is About Genetic Medicine And Diversified Revenue Stream

 
• By David Wild

PTC Therapeutics’ CEO Matthew Klein says the uncertainties of gene therapy development and commercialization have led to huge opportunity costs. After shelving PTC’s preclinical gene therapy programs, he is leveraging the company's diverse platforms and expanding its commercial efforts.

PTC Therapeutics Has Winnowed Its Programs But Still Sticking To Genetic Medicine • Source: Shutterstock

More from Business Strategy

More from In Vivo